Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics Appoints Jeffrey H. Knapp as Chief Operating Officer
— Operational Leadership and Deep Commercial Experience Key as Aimmune Launches Pivotal Phase 3 PALISADE Clinical Trial — BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 17, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food
Toggle Summary Aimmune Therapeutics to Present at the Piper Jaffray 27th Annual Healthcare Investor Conference
— Presentation on December 1, 2015 , at 2:00 p.m. ET — BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 16, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it will present at the Piper Jaffray 27th
Toggle Summary Aimmune Therapeutics Reports Positive Findings for ARC002 Follow-On Phase 2 Study of AR101 for Treatment of Peanut Allergy
— Aimmune Plans to Release Full ARC002 Data at AAAAI Meeting in March 2016 — BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 11, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced positive findings for its
Toggle Summary Aimmune Therapeutics Announces Financial Results for the Third Quarter 2015
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 4, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced financial results for the third quarter and nine months ended September 30, 2015 .
Toggle Summary Aimmune Therapeutics to Present at the 2015 Credit Suisse Healthcare Conference
— Presentation on November 11, 2015 , at 2:00 p.m. MT — BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 2, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it will present at the 2015 Credit Suisse
Toggle Summary Aimmune Therapeutics Announces COO Transition
— COO Howard Raff to Retire from Leadership Position to Focus on Future Pipeline Development — — Aimmune Builds Clinical Team with Key Allergist / Immunologist Hires — BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 9, 2015-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics Receives EMA Decision Agreeing With PIP for AR101 for the Treatment of Peanut Allergy
BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 7, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it has received the European Medicines Agency (EMA) decision endorsing the company’s pediatric
Toggle Summary Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
— Presentation on September 18, 2015 , at 9:45 a.m. GMT — BRISBANE, Calif. --(BUSINESS WIRE)--Sep. 2, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it will present at the Bank of America
Toggle Summary Aimmune Therapeutics Reports Second Quarter 2015 Financial Results
-- IPO Netted $168 Million for Strong Cash Position -- -- Phase 3 Trial Planned for Early 2016 Based on Successful Phase 2 Trial -- BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 31, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for
Toggle Summary Aimmune Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 11, 2015-- Aimmune Therapeutics, Inc. , today announced the closing of its initial public offering of 11,499,999 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions, which includes the